methyl 3-(3,5-difluoro-4-hydroxyphenyl)propanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: methyl 3-(3,5-difluoro-4-hydroxyphenyl)propanoate
• 英文别名: Methyl 3-(3,5-difluoro-4-hydroxyphenyl)propanoate
• 化学式: C₁₀H₁₀F₂O₃
• 分子量: 216.184
• InChiKey: HDHLNJNBVCFGDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 3-(3,5-difluoro-4-hydroxyphenyl)propanoate 、 在 三丁基膦 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of N -arylpyrroles as agonists of GPR120 for the treatment of type II diabetes

  摘要：

  The discovery of a novel series of N-arylpyrroles as agonists of GPR120 (FFAR4) is discussed. One lead compound is a potent GPR120 agonist, has good selectivity for related receptor GPR40 (FFAR1), has acceptable PK properties, and is active in 2 models of Type 2 Diabetes in mice.

  DOI：

  10.1016/j.bmcl.2018.02.013

文献信息

• [EN] SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS<br/>[FR] PYRAZOLES SUBSTITUÉS AGONISTES DU RÉCEPTEUR FFA4/GPR120
  申请人：AXXAM SPA

  公开号：WO2019175152A1

  公开（公告）日：2019-09-19

  The present invention refers to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. The invention refers also to pharmaceutical compositions comprising these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

  本发明涉及式(I)的化合物或其药学上可接受的盐：式(I)。这些化合物具有FFA4/GPR120受体（FFA4）激动性特性。该发明还涉及包含这些化合物的药物组合物，用于制备它们的化学过程以及它们在治疗或预防与动物（特别是人类）FFA4受体活性相关的疾病中的用途。
• [EN] ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] DÉRIVÉS ISOTHIAZOLE UTILES EN TANT QU'AGONISTES DE GPR120 POUR LE TRAITEMENT DU DIABÈTE DE TYPE II
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015134039A1

  公开（公告）日：2015-09-11

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

  揭示了一种通过调节GPR120受体而影响的疾病的化合物、组合物和治疗方法。这些化合物由以下式（I）表示：其中R1、G和Q在此处定义。
• Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
  申请人：Janssen Pharmaceutica NV

  公开号：US09067898B1

  公开（公告）日：2015-06-30

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

  揭示了一种通过调节GPR120受体来治疗受影响疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、G和Q在此处定义。
• GPR120 agonists for the treatment of type II diabetes
  申请人：Janssen Pharmaceutica NV

  公开号：US10118922B2

  公开（公告）日：2018-11-06

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

  公开了用于治疗受 GPR120 受体调节影响的疾病的化合物、组合物和方法。此类化合物由如下式（I）和式（II）表示： 其中 Y、R1、G 和 Q 在本文中定义； 和 其中 R11、R21、R41、RB1 和 G1 在本文中定义。
• US2014/275179
  申请人：——

  公开号：——

  公开（公告）日：——